Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical niosomal tranexamic acid + niacinamide for melasma
IRCT20220609055116N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of tranexamic acid, nicotinamide and hydroquinone in melasma (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Modified Melasma Area Severity Index, Melanin index and 1 more. Started Aug 2023; status: completed.
02
Drugs
tranexamic acidnicotinamidehydroquinone
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20220609055116N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220609055116N1.